Neuropace, Inc. (NPCE)
NASDAQ:NPCE
Want to see NPCE full AI Analyst Report?
NPCE Stock Chart & Stats
$14.09
-$0.66(-5.31%)
At close: 4:00 PM EST
$14.09
-$0.66(-5.31%)
Day’s Range― - ―
52-Week Range$7.56 - $19.60
Previous CloseN/A
Volume21.31K
Average Volume (3M)201.76K
Market Cap
$576.87M
Enterprise Value$632.55M
Total Cash (Recent Filing)$53.98M
Total Debt (Recent Filing)$70.46M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Aug 06, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding34,093,746
10 Day Avg. Volume230,602
30 Day Avg. Volume201,761
Financial Highlights & Ratios
PEG Ratio0.81
Price to Book (P/B)26.55
Price to Sales (P/S)5.05
P/FCF Ratio-44.56
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue6.36
Enterprise Value/Gross Profit8.12
Enterprise Value/Ebitda-42.51
Forecast
1Y Price Target
$19.75Price Target Upside40.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.58
Revenue Forecast (FY)$99.95M
Bulls Say, Bears Say
Bulls Say
High Gross Margins And Pricing PowerSustained gross margins above 80% imply durable unit economics for the RNS System, providing a large margin buffer to fund R&D and commercial expansion. High margins improve operating leverage potential and reduce sensitivity to reimbursement pressure, supporting long-term profitability if volume scales.
Robust Clinical Evidence And Regulatory EngagementStrong, FDA‑monitored clinical results and active regulatory interactions increase the probability of broader indications and payer consideration. Durable clinical evidence (including long‑term outcomes) underpins physician adoption, supports label expansion, and reduces future commercial resistance over months to years.
Commercial Expansion And AI Product RoadmapGrowing prescriber base and pipeline indicate improving market penetration and repeat procedure potential. Investment in AI and cloud tools builds differentiation and clinician stickiness, enabling service revenue growth and better patient outcomes that can widen the TAM and raise long‑term switching costs.
Bears Say
High Leverage And Thin Equity CushionElevated leverage with a materially compressed equity base reduces financial flexibility and heightens refinancing or covenant risk. In a capital‑intensive adoption cycle this raises the probability of dilution or higher funding costs, constraining strategic investments and resilience to demand shocks.
Negative Operating And Free Cash FlowPersistent negative cash generation requires external financing to sustain growth and operations. Continued cash burn, even if improved from prior years, shortens runway given current liquidity and high leverage, forcing tradeoffs between commercial investment, R&D, and potential dilution risk over the next several quarters.
Clinical Endpoint Uncertainty And Reimbursement LagA missed primary endpoint introduces label and review uncertainty that can slow payer coverage and clinician uptake for new indications. Even with positive secondary data, private payer adoption and expanded reimbursement will be gradual, delaying revenue benefits from potential indication expansions like IGE.
NeuroPace News
NPCE FAQ
What was Neuropace, Inc.’s price range in the past 12 months?
Neuropace, Inc. lowest stock price was $7.56 and its highest was $19.60 in the past 12 months.
What is Neuropace, Inc.’s market cap?
Neuropace, Inc.’s market cap is $576.87M.
When is Neuropace, Inc.’s upcoming earnings report date?
Neuropace, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 73 days.
How were Neuropace, Inc.’s earnings last quarter?
Neuropace, Inc. released its earnings results on May 12, 2026. The company reported -$0.132 earnings per share for the quarter, beating the consensus estimate of -$0.23 by $0.098.
Is Neuropace, Inc. overvalued?
According to Wall Street analysts Neuropace, Inc.’s price is currently Undervalued.
Does Neuropace, Inc. pay dividends?
Neuropace, Inc. does not currently pay dividends.
What is Neuropace, Inc.’s EPS estimate?
Neuropace, Inc.’s EPS estimate is -0.21.
How many shares outstanding does Neuropace, Inc. have?
Neuropace, Inc. has 34,093,746 shares outstanding.
What happened to Neuropace, Inc.’s price movement after its last earnings report?
Neuropace, Inc. reported an EPS of -$0.132 in its last earnings report, beating expectations of -$0.23. Following the earnings report the stock price went up 0.063%.
Which hedge fund is a major shareholder of Neuropace, Inc.?
Currently, no hedge funds are holding shares in NPCE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NeuroPace Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.75 (40.17% Upside)
$19.75 (40.17% Upside)
Blogger Sentiment
Bullish
NPCE Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 59.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 8.9%
Last 30 Days ▼ 8.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-5.31%
12-Months-Change
Fundamentals
Return on Equity
-120.74%
Trailing 12-Months
Asset Growth
-10.26%
Trailing 12-Months
Company Description
Neuropace, Inc.
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
NPCE Company Deck
NPCE Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial and clinical momentum: double-digit RNS revenue growth (CFO reported ~20% YoY excluding DIXI), raised full-year guidance, improved adjusted EBITDA outlook, robust clinical data (NAUTILUS 18-month and 3-year focal outcomes), and tangible AI/product roadmap progress. Offsetting risks include the NAUTILUS primary endpoint nuance, IGE revenue timing and payer coverage uncertainty, seasonally lower cash, and ongoing need for reimbursement work. Overall, management presented disciplined investment and operating leverage alongside meaningful opportunities that outweigh near-term risks.View all NPCE earnings summariesNPCE Stock 12 Month Forecast
Average Price Target
$19.75
▲(40.17% Upside)
Technical Analysis
Delcath Systems
―
Senseonics Holdings
―
Tactile Systems Technology
―
RxSight
―
Ceribell, Inc.
―
Ownership Overview
17.08% Insiders
9.57% Mutual Funds
42.19% Other Institutional Investors
16.08% Public Companies and
Individual Investors